CWM
BIIB icon

Cranbrook Wealth Management’s Biogen BIIB Stock Holding History

Cranbrook Wealth Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7
Closed -$1.07K – 429
2024
Q4 		$1.07K Hold
7
– – ﹤0.01% 364
2024
Q3 		$1.36K Buy
+7
New +$1.46K ﹤0.01% 334
2015
Q4 		– Sell
-30
Closed -$9K – 202
2015
Q3 		$9K Hold
30
– – 0.01% 163
2015
Q2 		$12K Buy
+30
New +$12K 0.01% 160
2014
Q1 		– Sell
-115
Closed -$32K – 157
2013
Q4 		$32K Buy
+115
New +$29.7K 0.02% 119

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cranbrook Wealth Management's BIIB Position: Q1 2025 in Review

Cranbrook Wealth Management sold out of Biogen (BIIB) in Q1 2025, closing a stake of 7 shares — an estimated $1.07K sold.

Cranbrook Wealth Management first reported a position in BIIB in Q4 2013 and held it in 5 quarters. The position peaked at $32K in Q4 2013. 883 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.

  • Cranbrook Wealth Management reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
  • Cranbrook Wealth Management sold 7 Biogen shares in Q1 2025, an estimated $1.07K.
  • Cranbrook Wealth Management first reported a position in Biogen in Q4 2013 and held it in 5 quarters.
  • Cranbrook Wealth Management's Biogen position peaked at $32K in Q4 2013.
  • 883 funds tracked by Wall St. Rank held Biogen as of Q1 2025.

Based on Cranbrook Wealth Management's 13F filing for Q1 2025, filed 11 Apr 2025.